Migraine is one form of disorder affecting the quality of life of patient. The term chronic migraine refers to a clinical condition summarized by migraines headache on fifteen days usually per monthly episode. Most commonly patients on pharmacotherapy of migraine include Ergot derivatives, Opioids, and Analgesics for a period range of ten days per month. The CGRP is involved in pathology and physiology of origin of neurovascular headaches via migraine at both peripheral and central levels. The CGRP is highly expressed in trigeminal neurons (small myelinated Ad and unmyelinated C fibers) co-localized with other neuropeptides (e.g., substance P). The CGRP levels are increased into external jugular venous blood ipsilateral to pain during headache phase of migraine attack. Also the saliva and serum CGRP levels are increased during migraine and interracially in patients with CM. Scope: Erenumab-aooe, CGRPr antagonist, being the latest approved drug administered via subcutaneous route as 70 mg per month for prophylactic regime of migraine in adult patients, the results documented as per clinical trials data are very promising and thus Erenumab-aooe is an emerging hope to improve quality of life. Conclusion: CM is not fully treated as the pharmacotherapy response is at the poor level and also limited pharmacotherapy is available, however the emergence of Erenumab- aooe, CGRPr antagonist as the one of the latest drug approval for the prophylaxis of migraine in adults.
Cite this article:
Ranjodh Jeet Singh. Erenumab-aooe: A promising monoclonal antibody for prophylactic pharmacotherapy in migraine. Research Journal of Pharmacy and Technology. 2021; 14(7):3993-7. doi: 10.52711/0974-360X.2021.00692
Ranjodh Jeet Singh. Erenumab-aooe: A promising monoclonal antibody for prophylactic pharmacotherapy in migraine. Research Journal of Pharmacy and Technology. 2021; 14(7):3993-7. doi: 10.52711/0974-360X.2021.00692 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-7-89
1. Buse D. et al. (2012). Headache impact of episodic and chronic migraine: results from the American Migraine Prevalence and Prevention study. Headache 52: 3–17.
3. International Headache Society, International classification of headache disorders. Cephalalgia 2004; 24(Sup.1):1–160.
4. Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache: analysis of factors. Headache. 1982; 22(2):66–68.
5. Critchley M. Migraine: From Cappadocia to Queen Square. Background to Migraine In: Smith R, ed. London: Heinemann. Volume 1; 1967.
6. Goyal M, Bansal M. Understanding migraine: an overview. IJCP 2010; 21(3):137-141.
7. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache.2003; 43:171-8.
8. Barbanti P, Aurilia C, Fofi L, et al. The role of anti-CGRP antibodies in the pathophysiology of primary headaches. Neurol Sci 2017; 38: 31–35.
10. Silberstein Stephen D et al. Chronic migraine-classification, characteristics and treatment. Nature Reviews Neurology2012; 8: 162-171.
11. Evers et al. acute therapy and prophylaxis of migraine. Neurology 2008; 27(10): 933-949.
12. Vu T et al: pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects. Pharm Res. 2017 Sep; 34(9): 1784-1795.
13. Deen M et al: Blocking CGRP in migraine patients- a review of pros and cons. J headache pain. 2017 sep 25; 18(1):96.
14. Available from: https://www.drugbank.ca/drugs/DB14039#fda-reference.